Toripalimab (Loqtorzi / Tuoyi)
Anti-PD-1 immunotherapy for nasopharyngeal carcinoma, esophageal cancer, melanoma, and other solid tumors.
What is Toripalimab?
What it targets
Blocks PD-1 ligand binding (PD-L1 and PD-L2) to reactivate exhausted T-cell immunity against cancer.
Who it may help
Patients with metastatic or recurrent nasopharyngeal carcinoma, esophageal cancer, melanoma, and other solid tumors who have good performance status and no uncontrolled autoimmune disease.
Why testing matters
Pathology confirmation, imaging, CBC, liver/kidney function, thyroid function, hepatitis/HIV screening, and PD-L1 testing where applicable.
Cancers Toripalimab treats
Toripalimab is approved and studied for multiple solid tumors depending on the treatment line and country.
| Nasopharyngeal Carcinoma (NPC) | FDA-approved first-line with cisplatin + gemcitabine for recurrent/metastatic or locally advanced disease. Single-agent option for disease progression after platinum chemotherapy. Standard of care in USA and Europe since 2023–2024. |
| Esophageal Squamous Cell Carcinoma (ESCC) | EMA-approved first-line in combination with cisplatin + paclitaxel. Approved in China since 2022 for first-line unresectable/recurrent/metastatic ESCC. JUPITER-06 trial demonstrated significantly improved progression-free survival vs chemotherapy alone. |
| Melanoma | FDA-approved and extensively used in China (Tuoyi) for unresectable or metastatic melanoma. China recently approved first-line toripalimab for melanoma based on MELATORCH study. Used after standard therapy failure or as first-line depending on country. |
| Renal Cell Carcinoma (RCC) | Approved in China for advanced RCC. Listed in National Reimbursement Drug List for RCC treatment. Clinical use in selected patients with metastatic disease. |
| Triple-Negative Breast Cancer (TNBC) | Approved in China in combination with nab-paclitaxel for metastatic or recurrent TNBC with PD-L1 CPS ≥ 1. TORCHLIGHT study demonstrated improved progression-free survival. |
| Hepatocellular Carcinoma (HCC) | Approved in China in combination with bevacizumab for first-line unresectable or metastatic HCC. HEPATORCH study showed superior efficacy vs sorafenib. Approved March 2025. |
Who may benefit from Toripalimab?
Eligibility depends on cancer type, disease stage, treatment line, country, and general health status. The following patients are typically considered candidates:
- Adults with metastatic or recurrent nasopharyngeal carcinoma who have not received prior systemic chemotherapy for recurrent or metastatic disease.
- Patients with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
- Adults with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma in first-line treatment setting.
- Patients with unresectable or metastatic melanoma with adequate performance status.
- People with good performance status (ECOG 0–1), adequate organ function (liver, kidney, lung), and no active uncontrolled infection.
- Patients without severe autoimmune disease, prior organ transplant, or uncontrolled diabetes, hypertension, or endocrine disorder.
How Toripalimab works
- Blocks the PD-1 checkpoint
- Reactivates T-cell immunity
- Improves tumor control
- Mechanism is checkpoint-independent of histology
Tests before starting Toripalimab
Your oncology team will request these investigations to confirm diagnosis, assess safety, and guide treatment planning.
| Pathology and imaging | Tissue biopsy confirming cancer histology. Baseline CT, MRI, or PET-CT to measure disease burden and stage. Repeat imaging every 8–12 weeks during treatment to assess response. |
| Complete blood count (CBC), metabolic panel | Baseline hemoglobin, platelets, white blood cell count, electrolytes, liver function (AST, ALT, bilirubin), kidney function (creatinine, eGFR) to confirm normal organ function before starting. |
| Thyroid and endocrine function | Baseline TSH, free T4 to detect autoimmune thyroiditis risk. Fasting blood sugar, HbA1c for diabetes screening. Repeat thyroid function every 6–8 weeks during treatment as hypothyroidism is common. |
| Infection screening | Hepatitis B and C serology, HIV status, tuberculosis screening (Mantoux or IGRA). Active viral infection or untreated TB is a relative contraindication. |
| PD-L1 and biomarkers | PD-L1 immunohistochemistry may be relevant for some indications (varies by cancer type and country). EBV DNA monitoring in nasopharyngeal carcinoma. Tumor mutational burden or MSI testing in select cases. |
| Pregnancy and reproductive health | Pregnancy test for all women of childbearing potential before starting (toripalimab is teratogenic). Discuss contraception and breastfeeding plans with your oncologist. |
How Toripalimab is given
Toripalimab is administered by intravenous infusion in a hospital or day-care setting under medical supervision.
| Dose and formulation | 3 mg/kg intravenous infusion once every 3 weeks. Weight-based dosing in most regimens. Supplied as a liquid injection for IV use. Dose may be held, delayed, or discontinued depending on side effects and response. |
| Infusion schedule and duration | First infusion lasts 60 minutes. Subsequent infusions 30 minutes (if well tolerated). Patients are monitored during and for 30 minutes after infusion for reactions. Treatment continues for up to 24 months or until disease progression or unacceptable toxicity. |
| Combination with chemotherapy | For first-line NPC: given with cisplatin 75 mg/m² + gemcitabine 1000 mg/m² every 3 weeks for up to 6 cycles, then toripalimab alone. For ESCC: given with cisplatin + paclitaxel. Always follow your oncologist's exact schedule. |
| Single-agent use | For later-line NPC after platinum-based chemotherapy, toripalimab is given as monotherapy 3 mg/kg every 3 weeks. No chemotherapy is combined. Dosing and duration are individualized based on response and tolerability. |
| Missed doses and dose modifications | Do not skip doses or change the schedule on your own. If a dose is delayed due to side effects, your oncologist will decide when to resume. Grade 3–4 immune-related side effects usually require dose delay or discontinuation and corticosteroid treatment. |
| Drug interactions and supportive care | Tell your oncologist about all medicines, supplements, and herbal products. Most cancer drugs and supportive care (anti-nausea, blood transfusions) are compatible. Live vaccines are contraindicated during treatment and shortly after. |
Possible benefits of Toripalimab
Clinical trials have demonstrated measurable benefits in eligible patients. Response depends on cancer type, tumor burden, immune status, and individual factors.
| Improved progression-free survival | In JUPITER-02 (NPC), toripalimab + chemotherapy achieved median PFS of 21.4 months vs 8.2 months with chemotherapy alone. In JUPITER-06 (ESCC), median PFS was significantly prolonged. Represents substantial delay in cancer growth. |
| Improved overall survival | JUPITER-02 showed median OS not reached vs 33.7 months for chemotherapy. JUPITER-06 demonstrated meaningful OS improvement. Long-term follow-up data show approximately 52% 5-year survival in ESCC. Benefit sustained over years in responders. |
| Higher response rates | Objective response rates (tumor shrinkage of 30%+) are significantly higher with toripalimab + chemotherapy than chemotherapy alone. Many patients achieve partial response; some achieve complete response. |
| Single-agent option for later-line disease | Patients with NPC who progress after chemotherapy can receive toripalimab monotherapy without additional chemotherapy, reducing cumulative toxicity and offering continued treatment benefit. |
| First FDA-approved therapy for NPC | Represents a major advance for NPC patients in the USA. Prior to approval, only chemotherapy and palliative care were standard options. Now standard first-line and later-line treatment. |
| Potential symptom improvement | Tumors that shrink often cause relief of pain, difficulty swallowing, breathing difficulty, or other local symptoms, improving quality of life despite continued treatment. |
Side effects of Toripalimab
Like all immunotherapies, toripalimab can cause side effects ranging from mild to severe. Most are manageable with medical support. Immune-related side effects can affect any organ.
| Fatigue | Very common, especially after chemotherapy cycles. May improve with rest, gentle exercise, adequate nutrition, and iron/B12 supplementation if deficient. Persistent fatigue warrants blood work to rule out anemia or thyroid disease. |
| Rash and itching | Skin reactions range from mild itching to severe blistering or peeling. Mild rash may respond to emollients and antihistamines. Severe rash requires dermatology review and possible immunosuppression. |
| Hypothyroidism | One of the most common immune-related side effects. Develops in up to 27% of patients. Presents as fatigue, weight gain, constipation, cold intolerance. Managed with levothyroxine; requires regular TSH monitoring. |
| Cough and pneumonitis | New or worsening cough may signal immune pneumonitis, a serious immune-related adverse event. Requires urgent imaging and possible high-dose steroids. Report cough, shortness of breath, or chest pain immediately. |
| Diarrhea and colitis | May range from mild loose stools to severe bloody diarrhea (immune colitis). Mild diarrhea responds to dietary modification and loperamide. Severe diarrhea requires stool studies, imaging, possible biopsy, and high-dose steroids. |
| Liver inflammation (hepatitis) | Elevated liver enzymes may develop silently or with jaundice, dark urine, abdominal pain. Routine monitoring catches most cases early. Severe hepatitis requires immediate drug discontinuation and corticosteroid therapy. |
| Kidney toxicity | Immune-mediated glomerulonephritis can elevate creatinine and proteinuria. Detected by routine urinalysis and kidney function tests. Managed with steroids and monitoring; dialysis rarely needed. |
| Endocrine dysfunction | Beyond thyroid, pituitary and adrenal inflammation (adrenalitis) can cause severe low blood pressure, electrolyte imbalance, and confusion. Requires urgent adrenal hormone replacement. |
Call your doctor urgently if you develop:
- New or worsening cough, chest pain, shortness of breath, or difficulty breathing (possible pneumonitis).
- Severe diarrhea (more than 7 stools/day), bloody stool, severe abdominal pain (possible colitis).
- Jaundice, dark urine, yellowing of eyes/skin, severe nausea, right upper abdominal pain (possible hepatitis).
- Severe headache, confusion, vision changes, fainting, extreme weakness (possible encephalitis or pituitary/adrenal crisis).
- Severe rash, blistering, peeling skin, or mouth ulcers (possible Stevens-Johnson syndrome or severe dermatitis).
- Chest pain, rapid heartbeat, severe dizziness, swelling in legs (possible myocarditis or pericarditis).
- High fever (>38.5°C/101.3°F), signs of infection, severe weakness, rapid breathing (possible infection or sepsis).
Safety precautions: tell your oncologist if you have or had
Certain medical conditions increase the risk of serious side effects. Your oncologist must review these before starting toripalimab.
- Autoimmune disease such as lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, multiple sclerosis, myasthenia gravis, or vasculitis.
- Organ transplant (kidney, heart, liver, lung) or stem cell transplant history. Checkpoint inhibitors may trigger graft rejection.
- Interstitial lung disease, pulmonary fibrosis, or previous severe pneumonitis (either from other drugs or radiotherapy).
- Liver disease, hepatitis B or C (inactive or active), cirrhosis, or history of significant alcohol-related liver injury.
- Kidney disease, reduced kidney function (eGFR <30), or history of severe glomerulonephritis.
- Thyroid disease (hyper- or hypothyroidism), adrenal insufficiency, pituitary disease, or uncontrolled diabetes or hypertension.
- Active infection (bacterial, viral, fungal, or tuberculosis). Toripalimab may impair infection control and increase risk of sepsis.
- Long-term use of corticosteroids or other immunosuppressants (may need adjustment; some conditions preclude toripalimab use).
- Pregnancy, plans to become pregnant within 6 months, or breastfeeding. Toripalimab is teratogenic and contraindicated in pregnancy.
- Prior severe allergic reaction or hypersensitivity to monoclonal antibodies or any component of toripalimab.
Combining Toripalimab with other treatments
Toripalimab is often combined with chemotherapy in approved settings. Combination approaches may improve outcomes but also increase toxicity.
| Toripalimab + cisplatin + gemcitabine (NPC) | FDA and EMA approved first-line regimen for metastatic/recurrent locally advanced NPC. Toripalimab given every 3 weeks with up to 6 cycles of chemotherapy, then toripalimab monotherapy. JUPITER-02 trial demonstrated superior PFS and OS vs chemotherapy alone. |
| Toripalimab + cisplatin + paclitaxel (ESCC) | EMA and China-approved first-line for unresectable/recurrent/metastatic esophageal squamous cell carcinoma. JUPITER-06 trial showed significantly prolonged PFS and OS. Patients receive combined therapy for 6 cycles, then maintenance toripalimab if tolerated. |
| Toripalimab + bevacizumab (HCC) | China-approved (March 2025) first-line for unresectable/metastatic hepatocellular carcinoma. HEPATORCH study showed superiority vs sorafenib. Combines immunotherapy with anti-angiogenic therapy to improve tumor control. |
| Toripalimab + nab-paclitaxel (TNBC) | China-approved for metastatic/recurrent triple-negative breast cancer with PD-L1 CPS ≥ 1. TORCHLIGHT study demonstrated improved PFS. Chemotherapy typically continues for 6–8 cycles; toripalimab may continue as monotherapy. |
| Toripalimab monotherapy (later-line NPC) | Single-agent use after platinum chemotherapy failure. Patients receive 3 mg/kg every 3 weeks without additional chemotherapy. Allows continued treatment benefit while reducing cumulative toxicity. |
| Do not combine with | Other checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab) without specific trial design. Live vaccines should be avoided. Other immunotherapies or TKIs may be discussed in clinical trial settings only. |
What if Toripalimab stops working?
Some cancers progress despite toripalimab (primary resistance), while others respond initially then develop resistance. Options depend on cancer type, prior treatments, and overall health.
| Confirm progression with imaging and biomarkers | Repeat CT/MRI/PET-CT every 8–12 weeks to measure response and detect progression. In NPC, EBV DNA monitoring may guide decisions. Liquid biopsy or repeat tissue biopsy in select cases to identify acquired mutations or resistance mechanisms. |
| Switch to chemotherapy or targeted therapy | For NPC or ESCC after toripalimab, consider non-platinum chemotherapy, gemcitabine, taxanes, or 5-FU-based regimens. For melanoma, BRAF/NRAS-mutant tumors may benefit from targeted therapy if genomics support it. |
| Explore another checkpoint inhibitor or combination | Consider nivolumab, pembrolizumab, or other PD-1/PD-L1 inhibitors, especially if prior response to toripalimab was partial. Some patients respond to sequential immunotherapy. Others benefit from immunotherapy + targeted/chemotherapy combinations in clinical trials. |
| Enroll in clinical trials | Patients with progressive disease are excellent candidates for trials exploring new drug combinations, higher-dose regimens, or novel agents. CancerFax can help identify trials in China, India, Singapore, South Korea, USA, and Europe. |
| Radiation, surgery, or locoregional therapy | For localized progressive disease, radiation to a single large lesion or surgical resection of accessible tumors may be considered. Locoregional therapies (TACE, HIFU, BNCT) may extend treatment options. |
| Palliative and supportive care | When curative options are exhausted, shift focus to symptom management, pain control, nutritional support, and maintaining quality of life. Hospice and end-of-life care discussions with family and palliative care team. |
Cost of Toripalimab treatment
Cost varies widely by country, hospital, regimen, number of cycles, and insurance coverage. Budget planning requires comprehensive estimates.
| Drug cost per infusion | In the USA, toripalimab (Loqtorzi) costs approximately USD 10,000–15,000 per 3-weekly infusion (price varies by payer negotiation). First-line with chemotherapy (6 cycles) plus maintenance toripalimab can total USD 300,000–500,000 over 24 months. |
| Cost in China (Tuoyi) | In China, Tuoyi is significantly cheaper due to local manufacturing and volume. First 12 indications are on the National Reimbursement Drug List (NRDL 2025), which substantially reduces patient out-of-pocket cost. Cost varies by city, hospital, and patient category. |
| Cost in India and other countries | India availability varies; import pathway and hospital sourcing affect cost. Prices in India are typically much lower than USA but availability depends on hospital stock, clinical trial access, or regulatory approval status at time of treatment. |
| Chemotherapy costs | First-line regimens include cisplatin (USD 500–2,000 per cycle) and gemcitabine (USD 1,000–3,000 per cycle). If combining toripalimab + chemotherapy, add these costs. Six cycles of chemotherapy may cost USD 30,000–50,000 in the USA. |
| Infusion day-care, premedications, supportive care | Infusion center charges USD 1,000–3,000 per visit. Premedications (antihistamines, acetaminophen, corticosteroids if immune reaction), antiemetics, growth factors, blood transfusions, and ER visits add USD 5,000–20,000 over treatment course. |
| Tests and monitoring | Baseline and periodic bloodwork, imaging (CT/MRI every 8–12 weeks), specialist visits, and pathology add USD 10,000–30,000 over the treatment period. More frequent testing in patients with complications. |
| Immune-related side effect management | Hospitalization for pneumonitis, colitis, hepatitis, or other severe immune events can cost USD 20,000–100,000+ per episode. High-dose corticosteroids, ICU stays, and specialist consultations add significant cost. |
| Financial assistance and insurance | In the USA, patient assistance programs through Coherus may reduce out-of-pocket cost. Insurance coverage varies; many plans cover FDA-approved indications but may require prior authorization. CancerFax can help navigate insurance and cost-sharing options. |
Availability of Toripalimab by region
Toripalimab approval and availability differ significantly by country. Confirm status before planning treatment.
USA (FDA)
Loqtorzi is FDA-approved for first-line NPC with cisplatin and gemcitabine, and as a single agent for recurrent/metastatic NPC after platinum chemotherapy, available through commercial distribution.
Europe (EMA)
Loqtorzi EMA-approved September 19, 2024. Approved for NPC with cisplatin + gemcitabine and ESCC with cisplatin + paclitaxel (first-line). Currently rolling out across EU member states. Availability and reimbursement vary by country.
China (NMPA)
Tuoyi is China's first domestic anti-PD-1 approved drug, with 13 indications including NPC, ESCC, melanoma, RCC, TNBC, HCC, and NSCLC. Most indications are on the NRDL with insurance coverage.
India
Regulatory approval and local availability vary. May be available through selected hospitals, clinical trials, or import pathways. CancerFax can check current import status, hospital supply, and trial access in India.
Other countries
Approval in Hong Kong, Singapore, South Korea, Australia, and other regions. Access varies by local regulatory status, hospital procurement, and clinical trial availability. CancerFax can research availability for your specific location.
Clinical trials and research
Toripalimab is being studied in multiple cancer types and combinations. Trials may offer access to newer regimens or explore emerging indications.
| JUPITER-02 (Phase 3, NPC) | Randomized, double-blind, placebo-controlled trial in 289 patients. Toripalimab + chemotherapy vs chemotherapy alone for first-line metastatic/recurrent NPC. Primary endpoint: PFS. Secondary: OS. Results: median PFS 21.4 vs 8.2 months, OS not reached vs 33.7 months. Published JAMA 2023. |
| POLARIS-02 (Phase 2, NPC) | Open-label single-arm trial. Toripalimab monotherapy for recurrent/metastatic NPC after platinum chemotherapy. Primary: ORR and DoR. Secondary: PFS, OS. Confirmed significant response rate supporting single-agent use. FDA approval based partly on this trial. |
| JUPITER-06 (Phase 3, ESCC) | Randomized, double-blind, placebo-controlled in patients with advanced ESCC. Toripalimab + cisplatin + paclitaxel vs chemotherapy alone. Results: significantly prolonged PFS and OS. 5-year survival rate ~52%. EMA approval based on this data. |
| MELATORCH (Phase 3, melanoma) | Randomized trial in 255 patients with untreated unresectable/metastatic melanoma. Toripalimab vs dacarbazine. Results: improved PFS and OS. Median PFS 2.3 vs 2.1 months; OS 15.1 vs 9.4 months. Led to China NMPA approval of toripalimab for first-line melanoma (April 2025). |
| HEPATORCH (Phase 3, HCC) | Multinational, open-label, active-controlled in 326 patients with unresectable/metastatic HCC. Toripalimab + bevacizumab vs sorafenib. Results: superior efficacy and safety profile. China NMPA approval March 2025. |
| TORCHLIGHT (Phase 3, TNBC) | Phase 3 trial in triple-negative breast cancer. Toripalimab + nab-paclitaxel vs chemotherapy alone for metastatic/recurrent TNBC (PD-L1 CPS ≥ 1). Interim analysis showed improved PFS. China NMPA approval. |
Your treatment journey with Toripalimab
1. Diagnosis confirmation
2. Eligibility assessment
3. Treatment planning
4. First infusion
5. Cycle management
6. Response assessment
7. Side-effect management
8. Maintenance and continuation
9. End of treatment and follow-up
Questions to ask your oncologist
- Is Toripalimab appropriate for my specific cancer type and disease stage?
- Is Toripalimab FDA/EMA/NMPA approved in my country, or would it be off-label?
- Do I need PD-L1 testing, EBV DNA testing, or other biomarker tests before starting?
- Will I receive Toripalimab alone or in combination with chemotherapy?
- How often will I receive infusions, and for how long?
- What side effects should I report immediately, and how do I contact you after hours?
- What blood tests and imaging will I need during treatment?
- Can I receive Toripalimab in India, China, or another country if it is not available locally?
How CancerFax can help
CancerFax specializes in navigating complex cancer care and international treatment access.
| Second opinion and treatment planning | Our oncology team reviews your pathology, imaging, and medical history to assess whether Toripalimab is appropriate and how it fits into your treatment strategy. We provide evidence-based guidance on regimen options, sequencing, and alternatives. |
| Medical report review and summary | We compile and organize your biopsy reports, imaging findings, prior treatment records, and blood work into a clear clinical summary that your doctors can use to guide decision-making and avoid repeated testing. |
| Specialist matching and coordination | We connect you with top oncologists experienced in Toripalimab and your specific cancer type. Whether in India, China, USA, Europe, or elsewhere, we coordinate care and facilitate communication between your local and international care teams. |
| China treatment access and logistics | China has 13 approved Tuoyi (Toripalimab) indications and many leading hospitals. We help identify the best centers for your cancer type, arrange medical visas, coordinate hospital admissions, and manage translation and logistics. |
| Clinical trial identification | Patients who progress on or ineligible for Toripalimab may benefit from clinical trials exploring newer combinations, alternative immunotherapies, or investigational drugs. We search India, China, Singapore, Korea, USA, and Europe for relevant trials. |
| Cost estimation and insurance navigation | Treatment costs vary dramatically by country and institution. We help you budget for Toripalimab, chemotherapy, monitoring, and side-effect management. We also guide navigation of insurance coverage, patient assistance programs, and financing options. |
Frequently asked questions
Common patient questions about Toripalimab
Response typically develops over 2 to 3 months of treatment. Some patients show rapid shrinkage within weeks; others require multiple cycles before imaging shows benefit. Blood tests and clinical assessment guide early signs of response (improvement in symptoms, energy level, or reduced fluid buildup).
The optimal duration of Toripalimab treatment is still being studied. In most approved regimens, treatment continues for up to 24 months or until disease progression or unacceptable toxicity. Stopping early against medical advice risks rapid relapse. Discuss with your oncologist if you wish to consider early stopping or maintenance strategies.
Toripalimab has no major interactions with common cancer drugs or supportive care medications. Live vaccines should be avoided during treatment and shortly after. Herbal supplements (especially immune-stimulating herbs) should be discussed with your oncologist. Always report all medications, supplements, and herbal products.
Yes. Several biosimilar versions of bevacizumab are available in different countries, including Mvasi and Zirabev in the USA and EU, and Abevmy and others in India. Biosimilars are approved on the basis of equivalent safety and efficacy to the originator product Avastin. Availability, pricing, and the specific indications for which biosimilars are approved can vary by country. Ask your oncologist or CancerFax whether a biosimilar is appropriate and available for your situation.
Infusion reactions (fever, chills, rash, wheezing, hypotension) are managed by slowing or pausing the infusion and giving antihistamines, acetaminophen, and corticosteroids as needed. Severe reactions may require emergency care. Most patients tolerate subsequent infusions without issue after premedication. Discuss risk factors and premedication strategy with your oncology team.